Takotsubo Syndrome Therapeutics Market-By Therapy (DAPT, Anticoagulants, Beta-blockers, Statins, Diuretics, ACE Inhibitors), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital, Retail Pharmacies), Global Forecast, (2022-2032)

Description

List of Tables

Global Takotsubo syndrome therapeutics market will grow at 4.7% CAGR from 2023 to 2032. Better understanding of the condition and improved diagnostic techniques have led to more accurate and timely treatment, fueling market growth. Increased awareness of the syndrome among healthcare professionals and the general population has led to earlier intervention, which is expected to drive industry expansion.

Additionally, the development of medications and therapies for addressing the underlying causes of stress-related heart conditions will contribute to business growth. The rising incidence of stress-related disorders in modern society has heightened the demand for effective takotsubo syndrome therapeutics, propelling market expansion.

In February 2022, Galderma and Taro Pharmaceutical Industries Ltd. announced a formal agreement wherein Taro would acquire Alchemee, previously known as The Proactiv Company (TPC), from Galderma.

The overall market is categorized based on therapy, route of administration, distribution channel, and region.

Based on therapy, the anticoagulants segment will reflect a 4.8% CAGR during the analysis period, driven by the need to manage thrombotic complications associated with the condition. Anticoagulants are crucial in preventing blood clots and minimizing the risk of stroke or other cardiovascular complications, thereby enhancing patient care and outcomes.

The parenteral route of administration segment is expected to exhibit a 4.3% CAGR during 2023-2032. The need for rapid and direct drug delivery will foster growth in the segment. Parenteral administration ensures immediate and precise medication distribution, which is crucial in managing acute takotsubo episodes and achieving effective symptom relief.

Based on distribution channel, the retail pharmacies segment will depict a 4.4% CAGR through 2032. The accessibility and patient convenience offered by retail pharmacies will drive growth in the segment. Retail pharmacies offer easy access to prescribed medications, making it more convenient for patients to obtain necessary therapeutics and adhere to treatment regimens, improving patient outcomes.

Regionally, the Asia Pacific takotsubo syndrome therapeutics market will witness a 5.4% CAGR throughout the forecast period. Growing awareness, better healthcare infrastructure, rising cardiovascular disease prevalence, and an aging population will boost the region's industry. Evolving healthcare priorities drive therapeutic research and development, further spurring growth.

Product Code: 6535

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Global takotsubo syndrome therapeutics market 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Therapy trends
- 2.1.4 Route of administration trends
- 2.1.5 Distribution channel trends

Chapter 3 Takotsubo Syndrome Therapeutics Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing geriatric population
  - 3.2.1.2 Advancements in diagnostic techniques
  - 3.2.1.3 Advances in personalized medicine and tailored treatment
  - 3.2.1.4 Increasing prevalence of cardiovascular diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limited understanding of underlying mechanisms behind takotsubo syndrome
  - 3.2.2.2 Lack of specific treatment guidelines
  - 3.2.2.3 High cost of treatment
3.3 Growth potential analysis
- 3.3.1 By therapy
- 3.3.2 By route of administration
- 3.3.3 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Technology landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company positioning matrix
4.4 Competitive analysis of major market players
4.5 Strategic outlook matrix

Chapter 5 Takotsubo Syndrome Therapeutics Market Size and Forecast, By Therapy (USD Million)

5.1 Key trends, by therapy
5.2 Dual antiplatelet therapy (DAPT)
5.3 Anticoagulants
5.4 Beta-blockers
5.5 Angiotensin-converting enzyme (ACE) inhibitors
5.6 Aldosterone receptor blockers
5.7 Statins
5.8 Diuretics

Chapter 6 Takotsubo Syndrome Therapeutics Market Size and Forecast, By Route of Administration (USD Million)

6.1 Key trends, by route of administration
6.2 Oral
6.3 Parenteral

Chapter 7 Takotsubo Syndrome Therapeutics Market Size and Forecast, By Distribution Channel (USD Million)

7.1 Key trends, by distribution channel
7.2 Hospital pharmacies
7.3 Retail pharmacies/ drug stores
7.4 Other distribution channels

Chapter 8 Takotsubo Syndrome Therapeutics Market Size and Forecast, By Region (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

9.1 Sanofi SA
9.2 Pfizer Inc.
9.3 AbbVie Inc.
9.4 ANI Pharmaceuticals, Inc.
9.5 Novartis AG
9.6 GlaxoSmithKline plc
9.7 Taro Pharmaceutical Industries Ltd.
9.8 Amneal Pharmaceuticals LLC.
9.9 Teva Pharmaceutical Industries Ltd.
9.10 Sun Pharmaceutical Industries Ltd.